Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 83

1.

A Comprehensive Analysis of the Dynamic Response to Aphidicolin-Mediated Replication Stress Uncovers Targets for ATM and ATMIN.

Mazouzi A, Stukalov A, Müller AC, Chen D, Wiedner M, Prochazkova J, Chiang SC, Schuster M, Breitwieser FP, Pichlmair A, El-Khamisy SF, Bock C, Kralovics R, Colinge J, Bennett KL, Loizou JI.

Cell Rep. 2016 Apr 14. pii: S2211-1247(16)30366-7. doi: 10.1016/j.celrep.2016.03.077. [Epub ahead of print]

2.

A Surface Biotinylation Strategy for Reproducible Plasma Membrane Protein Purification and Tracking of Genetic and Drug-Induced Alterations.

Hörmann K, Stukalov A, Müller AC, Heinz LX, Superti-Furga G, Colinge J, Bennett KL.

J Proteome Res. 2016 Feb 5;15(2):647-58. doi: 10.1021/acs.jproteome.5b01066. Epub 2016 Jan 12.

PMID:
26699813
3.

Superoxide Dismutase 1 Protects Hepatocytes from Type I Interferon-Driven Oxidative Damage.

Bhattacharya A, Hegazy AN, Deigendesch N, Kosack L, Cupovic J, Kandasamy RK, Hildebrandt A, Merkler D, Kühl AA, Vilagos B, Schliehe C, Panse I, Khamina K, Baazim H, Arnold I, Flatz L, Xu HC, Lang PA, Aderem A, Takaoka A, Superti-Furga G, Colinge J, Ludewig B, Löhning M, Bergthaler A.

Immunity. 2015 Nov 17;43(5):974-86. doi: 10.1016/j.immuni.2015.10.013.

4.

Germline RBBP6 mutations in familial myeloproliferative neoplasms.

Harutyunyan AS, Giambruno R, Krendl C, Stukalov A, Klampfl T, Berg T, Chen D, Milosevic Feenstra JD, Jäger R, Gisslinger B, Gisslinger H, Rumi E, Passamonti F, Pietra D, Müller AC, Parapatics K, Breitwieser FP, Herrmann R, Colinge J, Bennett KL, Superti-Furga G, Cazzola M, Hammond E, Kralovics R.

Blood. 2016 Jan 21;127(3):362-5. doi: 10.1182/blood-2015-09-668673. Epub 2015 Nov 16. No abstract available.

PMID:
26574608
5.

Gene essentiality and synthetic lethality in haploid human cells.

Blomen VA, Májek P, Jae LT, Bigenzahn JW, Nieuwenhuis J, Staring J, Sacco R, van Diemen FR, Olk N, Stukalov A, Marceau C, Janssen H, Carette JE, Bennett KL, Colinge J, Superti-Furga G, Brummelkamp TR.

Science. 2015 Nov 27;350(6264):1092-6. doi: 10.1126/science.aac7557. Epub 2015 Oct 15.

PMID:
26472760
6.

Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling.

Huber KV, Olek KM, Müller AC, Tan CS, Bennett KL, Colinge J, Superti-Furga G.

Nat Methods. 2015 Nov;12(11):1055-7. doi: 10.1038/nmeth.3590. Epub 2015 Sep 21.

7.

[Radiomics: Definition and clinical development].

Bourgier C, Colinge J, Aillères N, Fenoglietto P, Brengues M, Pèlegrin A, Azria D.

Cancer Radiother. 2015 Oct;19(6-7):532-7. doi: 10.1016/j.canrad.2015.06.008. Epub 2015 Sep 3. French.

PMID:
26344440
8.

The Lipid-Modifying Enzyme SMPDL3B Negatively Regulates Innate Immunity.

Heinz LX, Baumann CL, Köberlin MS, Snijder B, Gawish R, Shui G, Sharif O, Aspalter IM, Müller AC, Kandasamy RK, Breitwieser FP, Pichlmair A, Bruckner M, Rebsamen M, Blüml S, Karonitsch T, Fauster A, Colinge J, Bennett KL, Knapp S, Wenk MR, Superti-Furga G.

Cell Rep. 2015 Jun 30;11(12):1919-28. doi: 10.1016/j.celrep.2015.05.006. Epub 2015 Jun 18.

9.

A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.

Fauster A, Rebsamen M, Huber KV, Bigenzahn JW, Stukalov A, Lardeau CH, Scorzoni S, Bruckner M, Gridling M, Parapatics K, Colinge J, Bennett KL, Kubicek S, Krautwald S, Linkermann A, Superti-Furga G.

Cell Death Dis. 2015 May 21;6:e1767. doi: 10.1038/cddis.2015.130.

10.

Targeting a cell state common to triple-negative breast cancers.

Muellner MK, Mair B, Ibrahim Y, Kerzendorfer C, Lechtermann H, Trefzer C, Klepsch F, Müller AC, Leitner E, Macho-Maschler S, Superti-Furga G, Bennett KL, Baselga J, Rix U, Kubicek S, Colinge J, Serra V, Nijman SM.

Mol Syst Biol. 2015 Feb 19;11(1):789. doi: 10.15252/msb.20145664.

11.

The RNA-binding protein HuR/ELAVL1 regulates IFN-β mRNA abundance and the type I IFN response.

Herdy B, Karonitsch T, Vladimer GI, Tan CS, Stukalov A, Trefzer C, Bigenzahn JW, Theil T, Holinka J, Kiener HP, Colinge J, Bennett KL, Superti-Furga G.

Eur J Immunol. 2015 May;45(5):1500-11. doi: 10.1002/eji.201444979. Epub 2015 Mar 12.

12.

Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity.

Willmann KL, Klaver S, Doğu F, Santos-Valente E, Garncarz W, Bilic I, Mace E, Salzer E, Conde CD, Sic H, Májek P, Banerjee PP, Vladimer GI, Haskoloğlu S, Bolkent MG, Küpesiz A, Condino-Neto A, Colinge J, Superti-Furga G, Pickl WF, van Zelm MC, Eibel H, Orange JS, Ikincioğulları A, Boztuğ K.

Nat Commun. 2014 Nov 19;5:5360. doi: 10.1038/ncomms6360.

13.

NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.

Licciardello MP, Müllner MK, Dürnberger G, Kerzendorfer C, Boidol B, Trefzer C, Sdelci S, Berg T, Penz T, Schuster M, Bock C, Kralovics R, Superti-Furga G, Colinge J, Nijman SM, Kubicek S.

Oncogene. 2015 Jul;34(29):3780-90. doi: 10.1038/onc.2014.319. Epub 2014 Sep 29.

PMID:
25263445
14.

Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics.

Gridling M, Ficarro SB, Breitwieser FP, Song L, Parapatics K, Colinge J, Haura EB, Marto JA, Superti-Furga G, Bennett KL, Rix U.

Mol Cancer Ther. 2014 Nov;13(11):2751-62. doi: 10.1158/1535-7163.MCT-14-0152. Epub 2014 Sep 4.

15.

The triggering receptor expressed on myeloid cells 2 inhibits complement component 1q effector mechanisms and exerts detrimental effects during pneumococcal pneumonia.

Sharif O, Gawish R, Warszawska JM, Martins R, Lakovits K, Hladik A, Doninger B, Brunner J, Korosec A, Schwarzenbacher RE, Berg T, Kralovics R, Colinge J, Mesteri I, Gilfillan S, Salmaggi A, Verschoor A, Colonna M, Knapp S.

PLoS Pathog. 2014 Jun 12;10(6):e1004167. doi: 10.1371/journal.ppat.1004167. eCollection 2014 Jun.

16.

Comprehensive comparative and semiquantitative proteome of a very low number of native and matched epstein-barr-virus-transformed B lymphocytes infiltrating human melanoma.

Maurer M, Müller AC, Parapatics K, Pickl WF, Wagner C, Rudashevskaya EL, Breitwieser FP, Colinge J, Garg K, Griss J, Bennett KL, Wagner SN.

J Proteome Res. 2014 Jun 6;13(6):2830-45. doi: 10.1021/pr401270y. Epub 2014 May 6.

PMID:
24803318
17.

Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by IL-21 deficiency.

Salzer E, Kansu A, Sic H, Májek P, Ikincioğullari A, Dogu FE, Prengemann NK, Santos-Valente E, Pickl WF, Bilic I, Ban SA, Kuloğlu Z, Demir AM, Ensari A, Colinge J, Rizzi M, Eibel H, Boztug K.

J Allergy Clin Immunol. 2014 Jun;133(6):1651-9.e12. doi: 10.1016/j.jaci.2014.02.034. Epub 2014 Apr 17.

PMID:
24746753
18.

TOPS: a versatile software tool for statistical analysis and visualization of combinatorial gene-gene and gene-drug interaction screens.

Muellner MK, Duernberger G, Ganglberger F, Kerzendorfer C, Uras IZ, Schoenegger A, Bagienski K, Colinge J, Nijman SM.

BMC Bioinformatics. 2014 Apr 8;15:98. doi: 10.1186/1471-2105-15-98.

19.

Building and exploring an integrated human kinase network: global organization and medical entry points.

Colinge J, César-Razquin A, Huber K, Breitwieser FP, Májek P, Superti-Furga G.

J Proteomics. 2014 Jul 31;107:113-27. doi: 10.1016/j.jprot.2014.03.028. Epub 2014 Apr 3.

20.

Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.

Huber KV, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A, Jemth AS, Göktürk C, Sanjiv K, Strömberg K, Pham T, Berglund UW, Colinge J, Bennett KL, Loizou JI, Helleday T, Knapp S, Superti-Furga G.

Nature. 2014 Apr 10;508(7495):222-7. doi: 10.1038/nature13194. Epub 2014 Apr 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk